- Home
- PTCT
PTCT
PTC Therapeutics Inc.
as 04-01-2025 4:00pm EST
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | WARREN |
| Market Cap: | N/A | IPO Year: | 2013 |
| Target Price: | $63.77 | AVG Volume (30 days): | 919.9K |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $24.00 - $58.38 | Next Earning Date: | 04-24-2025 |
| Revenue: | $806,780,000 | Revenue Growth: | -13.97% |
| Revenue Growth (this year): | -8.95% | Revenue Growth (next year): | 16.92% |
Stock Insider Trading Activity of PTC Therapeutics Inc. (PTCT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Pauwels Eric | PTCT | CHIEF BUSINESS OFFICER | Mar 14 '25 | Sell | $56.61 | 11,220 | $630,104.40 | 77,365 | |
| Okey Stephanie | PTCT | Director | Mar 13 '25 | Sell | $54.00 | 5,000 | $270,000.00 | 8,867 | |
| Boulding Mark Elliott | PTCT | EXEC. VP AND CLO | Mar 12 '25 | Sell | $53.27 | 15,521 | $827,232.91 | 103,901 | |
| Boulding Mark Elliott | PTCT | EXEC. VP AND CLO | Mar 10 '25 | Sell | $52.93 | 75,420 | $4,003,304.97 | 103,901 | |
| Jacobson Allan Steven | PTCT | Director | Mar 4 '25 | Sell | $51.52 | 1,230 | $63,369.60 | 19,118 | |
| Klein Matthew B. | PTCT | CHIEF EXECUTIVE OFFICER | Feb 19 '25 | Sell | $50.11 | 7,792 | $390,457.09 | 279,933 | |
| Utter Christine Marie | PTCT | SVP, CHIEF ACCOUNTING OFFICER | Feb 19 '25 | Sell | $50.11 | 1,757 | $88,043.26 | 63,442 | |
| Pauwels Eric | PTCT | CHIEF EXECUTIVE OFFICER | Feb 19 '25 | Sell | $50.11 | 2,945 | $147,576.60 | 77,365 | |
| Almstead Neil Gregory | PTCT | CHIEF TECHNICAL OPS OFFICER | Feb 19 '25 | Sell | $50.11 | 2,946 | $147,627.95 | 5,907 | |
| Boulding Mark Elliott | PTCT | EXEC. VP AND CLO | Feb 19 '25 | Sell | $50.11 | 2,947 | $147,678.10 | 103,901 |
Latest PTC Therapeutics Inc. News
PTCT Breaking Stock News: Dive into PTCT Ticker-Specific Updates for Smart Investing
PR Newswire
5 days ago
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
5 days ago
Sector Update: Health Care Stocks Mixed Friday Afternoon
MT Newswires
5 days ago
PTC Therapeutics Loses EU Authorization for Translarna in Duchenne Muscular Dystrophy
PR Newswire
5 days ago
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe
PR Newswire
13 days ago
PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies
Zacks
a month ago
Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?
Simply Wall St.
a month ago
PTC Therapeutics, Inc. (NASDAQ:PTCT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates
Simply Wall St.
a month ago
We Might See A Profit From PTC Therapeutics, Inc. (NASDAQ:PTCT) Soon
Compare PTCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PTCT PTC Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.